Duloxetine reduces morphine requirements after knee replacement surgery

Area of Science:

• Anesthesiology and Pain Management
• Pharmacology
• Orthopedic Surgery

Background:

• Multimodal analgesia is recommended for perioperative pain to minimize opioid-related adverse effects.
• Serotonin and norepinephrine pathways are crucial for endogenous pain inhibition.
• Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is effective for chronic pain conditions.

Purpose of the Study:

• To assess the efficacy of duloxetine in decreasing intraoperative and postoperative morphine consumption in patients undergoing knee replacement surgery.

Main Methods:

• A randomized controlled trial involving 50 patients undergoing knee replacement.
• Patients received either two doses of oral duloxetine (60 mg) or a placebo.
• Postoperative pain and morphine requirements were monitored for 48 hours using patient-controlled analgesia.

Main Results:

• A significant reduction in 48-hour postoperative morphine requirements was observed in the duloxetine group (19.5 mg) compared to the placebo group (30.3 mg) (P=0.017).
• No significant differences in pain scores (at rest or during movement) were found between the groups.
• There were no statistically significant differences in the incidence of adverse effects between the duloxetine and placebo groups.

Conclusions:

• Perioperative administration of duloxetine effectively reduces morphine requirements in the initial 48 hours following knee replacement surgery.
• Duloxetine can be considered a valuable component of multimodal analgesia for knee replacement, enhancing pain management without increasing side effects.